RXRX Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

$9.31  +0.01 (0.11%)
As of 12/02/2022 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/18/2002
Outstanding shares:  181,694,536
Average volume:  1,400,509
Market cap:   $1,689,759,185
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BM9FJ13
Valuation   (See tab for details)
PE ratio:   -7.98
PB ratio:   3.22
PS ratio:   215.75
Return on equity:   -42.90%
Net income %:   -2,703.54%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy